Japan’s Eisai Says It Still Has Patent Protection For Aricept Despite Court Action (Japan)
This article was originally published in PharmAsia News
Executive Summary
Japan's Eisai says a U.S. district court ruling will have no impact on the validity of its patent for Aricept (donepezil hydrochloride) for treating Alzheimer's disease. The court in New Jersey threw out Eisai's suit against Mutual Pharmaceutical for seeking U.S. FDA approval for an Aricept generic. Eisai said the ruling was based on procedural grounds and it is still free to sue Mutual to defend a patent not set to expire until 2010. (Click here for more - may require a subscription
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.